Comments
Suven Life Sciences on Thursday informed the exchanges that it has secured process patents from Europe, Japan and New Zealand for new chemical entities (NCEs) used for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2034, it added. These process patents are for the company’s pipeline compounds which are in the class of selective 5HT6 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s disease and schizophrenia. Shares of Suven Life jumped 3.96 per cent at ₹163.80 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.